BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19520775)

  • 1. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant.
    Iwai M; Minematsu T; Narikawa S; Usui T; Kamimura H
    Drug Metab Dispos; 2009 Sep; 37(9):1856-63. PubMed ID: 19520775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
    Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
    Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
    Minematsu T; Iwai M; Sugimoto K; Shirai N; Nakahara T; Usui T; Kamimura H
    Drug Metab Dispos; 2009 Mar; 37(3):619-28. PubMed ID: 19056913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein.
    Iwai M; Minematsu T; Li Q; Iwatsubo T; Usui T
    Drug Metab Dispos; 2011 Dec; 39(12):2314-20. PubMed ID: 21918035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cryopreservation on the activity of OATP1B1/3 and OCT1 in isolated human hepatocytes.
    Badolo L; Trancart MM; Gustavsson L; Chesné C
    Chem Biol Interact; 2011 Apr; 190(2-3):165-70. PubMed ID: 21356203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats.
    Umehara KI; Iwatsubo T; Noguchi K; Kamimura H
    Xenobiotica; 2007 Aug; 37(8):818-31. PubMed ID: 17701831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity.
    Tu M; Sun S; Wang K; Peng X; Wang R; Li L; Zeng S; Zhou H; Jiang H
    Toxicology; 2013 Sep; 311(3):225-30. PubMed ID: 23831208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
    Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
    Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
    Nies AT; Herrmann E; Brom M; Keppler D
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):449-61. PubMed ID: 18157518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.
    Morse BL; Fallon JK; Kolur A; Hogan AT; Smith PC; Hillgren KM
    AAPS J; 2021 Apr; 23(3):58. PubMed ID: 33903987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes.
    De Bruyn T; Ye ZW; Peeters A; Sahi J; Baes M; Augustijns PF; Annaert PP
    Eur J Pharm Sci; 2011 Jul; 43(4):297-307. PubMed ID: 21605667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake.
    Morse BL; Kolur A; Hudson LR; Hogan AT; Chen LH; Brackman RM; Sawada GA; Fallon JK; Smith PC; Hillgren KM
    Drug Metab Dispos; 2020 Feb; 48(2):93-105. PubMed ID: 31771949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
    Satoh T; Okamoto I; Miyazaki M; Morinaga R; Tsuya A; Hasegawa Y; Terashima M; Ueda S; Fukuoka M; Ariyoshi Y; Saito T; Masuda N; Watanabe H; Taguchi T; Kakihara T; Aoyama Y; Hashimoto Y; Nakagawa K
    Clin Cancer Res; 2009 Jun; 15(11):3872-80. PubMed ID: 19470738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats.
    Minematsu T; Sonoda T; Hashimoto T; Iwai M; Oppeneer T; Felder L; Shirai N; Miyashita A; Usui T
    Biopharm Drug Dispos; 2012 Apr; 33(3):160-9. PubMed ID: 22374735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats.
    Maeda T; Oyabu M; Yotsumoto T; Higashi R; Nagata K; Yamazoe Y; Tamai I
    Drug Metab Dispos; 2007 Sep; 35(9):1580-6. PubMed ID: 17553914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype.
    Fattah S; Shinde AB; Matic M; Baes M; van Schaik RHN; Allegaert K; Parmentier C; Richert L; Augustijns P; Annaert P
    Pharm Res; 2017 Jun; 34(6):1309-1319. PubMed ID: 28364304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP.
    Zhang Y; Ruggiero M; Hagenbuch B
    Drug Metab Dispos; 2020 Aug; 48(8):622-630. PubMed ID: 32482756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.